Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Immutep Limited
  6. News
  7. Summary
    IMM   AU000000IMM6

IMMUTEP LIMITED

(IMM)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about IMMUTEP LIMITED
02:32pIMMUTEP : Maxim Group - The Case for LAG-3 is Building
PU
02:12pIMMUTEP : ESMO 2021 – INSIGHT - Stratum D Poster
PU
09/02IMMUTEP : Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients..
PU
09/01IMMUTEP : Completes Patient Enrollment in Stage 2 of Part B of NSCLC Study; Shar..
MT
09/01IMMUTEP : PRELIMINARY FINAL REPORT (Form 6-K)
PU
09/01IMMUTEP : Completes Recruitment, Dosing in Phase 2 Trial of Non-Small Cell Lung ..
MT
09/01IMMUTEP : Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients..
PU
08/31Immutep Limited Announces Recruitment of Patients Completed for Part B of TAC..
CI
08/31IMMUTEP : Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
AQ
08/31IMMUTEP : Chinese Partner to Expand Clinical Trial Pipeline for Cancer Drug
MT
08/31IMMUTEP : S CHINESE PARTNER, EOC PHARMA, EXPANDS EFTI TRIAL PIPELINE (Form 6-K)
PU
08/30IMMUTEP : Partner, EOC Pharma, Expands Efti Trial Pipeline
PU
08/30IMMUTEP : Maxim Group - Annual FY Update; AIPAC Final Data Approaching
PU
08/30Immutep Limited Reports Earnings Results for the Full Year Ended June 30, 202..
CI
08/27IMMUTEP : ANNOUNCES CHINESE PATENT GRANT FOR LAG-3 ANTAGONIST ANTIBODY LAG525 (F..
PU
More most relevant news
All news about IMMUTEP LIMITED
02:32pIMMUTEP : Maxim Group - The Case for LAG-3 is Building
PU
02:12pIMMUTEP : ESMO 2021 – INSIGHT - Stratum D Poster
PU
09/02IMMUTEP : Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients..
PU
09/01IMMUTEP : Completes Patient Enrollment in Stage 2 of Part B of NSCLC Study; Shar..
MT
09/01IMMUTEP : PRELIMINARY FINAL REPORT (Form 6-K)
PU
09/01IMMUTEP : Completes Recruitment, Dosing in Phase 2 Trial of Non-Small Cell Lung ..
MT
09/01IMMUTEP : Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients..
PU
08/31Immutep Limited Announces Recruitment of Patients Completed for Part B of TAC..
CI
08/31IMMUTEP : Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
AQ
08/31IMMUTEP : Chinese Partner to Expand Clinical Trial Pipeline for Cancer Drug
MT
More news
News in other languages on IMMUTEP LIMITED
09/01Immutep achève le recrutement de patients dans la phase 2 de la partie B de l..
09/01Immutep termine le recrutement et le dosage dans l'essai de phase 2 de la bit..
08/31Le partenaire chinois d'Immutep élargit son portefeuille d'essais cliniques p..
More news
Analyst Recommendations on IMMUTEP LIMITED
08/03IMMUTEP : Ladenburg Thalmann Starts Immutep at Buy With $8.30 Price Target
MT
More recommendations
Press releases
02:32pIMMUTEP : Maxim Group - The Case for LAG-3 is Building
PU
02:12pIMMUTEP : ESMO 2021 – INSIGHT - Stratum D Poster
PU
09/02IMMUTEP : Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients..
PU
09/01IMMUTEP : PRELIMINARY FINAL REPORT (Form 6-K)
PU
09/01IMMUTEP : Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients..
PU
More press releases
Upcoming event on IMMUTEP LIMITED